Prevalence of etravirine genotypic resistance was assessed among 92 HIV-1C-infected patients failing nevirapine and efavirenz-based regimens from a cohort of 552 Indian patients. Overall, prevalence of etravirine cross-resistance identified using the Tibotec Weighted Score was 41% (31.5% intermediately-resistant and 9.8% fully-resistant). The most frequently described nonnucleoside reverse transcriptase inhibitor-associated mutations included Y181 (35.9%), K101 (20.7%), G190 (17.4%), and V108 (15.2%). The resistant group demonstrated higher viral load (P = 0.01) and longer duration of antiretroviral treatment (P = 0.03) compared with the susceptible group.
aSt John's National Academy of Health Sciences, Bangalore, India
bDivision of Global Health, Sweden
cDepartment of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden
dDepartment of Medicine, Center for AIDS Prevention Studies, University of California, San Francisco, San Francisco, California, USA.
Received 11 November, 2010
Revised 16 February, 2011
Accepted 24 February, 2011
Correspondence to Maria L. Ekstrand, PhD, University of California, San Francisco, 50 Beale Street, Suite-1300, San Francisco, CA 94105, USA. E-mail: firstname.lastname@example.org